Computational biology

Jul 03, 2025

No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier

Chai Discovery's co-founders discuss Chai 2, their new generative AI platform for antibody design. It achieves a nearly 20% hit rate from just 20 computational attempts, a 100-fold improvement over previous methods, signaling a shift from drug discovery to drug engineering.

Jun 05, 2025

A quest for a cure: AI drug design with Isomorphic Labs

Experts from Isomorphic Labs discuss how AI, particularly models like AlphaFold3, is revolutionizing drug discovery. They explain the shift from the slow, iterative process of traditional methods to a new era where generative AI can design novel molecules, optimize for multiple biological properties simultaneously, and pave the way for personalized medicine.